DE · 88Q.DE
4basebio PLC
Programmatic access: valuation JSON for this ticker · catalog · agent briefing · agent card. Paid lookups: HTTP 402 then Payment-Authorization, or Authorization: Bearer ic_live_….
Price · as of 2026-09-07
$5.65
Market cap 81.3M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for 4basebio PLC (88Q.DE) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About 4basebio PLC
4basebio Plc is a biotechnology company, which engages in the business of developing advanced therapy medicinal products through synthetic DNA products and non-viral, cell targeting nucleic acid delivery platforms. The firm is involved in manufacturing and supplying high quality synthetic DNA products for research, therapeutic, and pharmacological use; and developing target specific non-viral vectors for the efficient delivery of payloads in patients. The company was founded on December 22, 2020 and is headquartered in Cambridge, the United Kingdom.
- CEO
- Amy Jo Walker
- Employees
- 101
- Beta
- 0.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.